** Shares of Soleno Therapeutics SLNO.O rise 33.98% to $65.61 premarket
** Late on Wednesday, U.S. FDA approved co's drug to treat a rare genetic disorder, making it first treatment available for patients who experience feelings of intense and persistent hunger
** The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder that is caused by an error in one or more genes
** The drug will have an annual average cost of $466,200 and will be dosed as per patients' weight and will be available from April
** Up to last close, stock up ~9% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.